Yang Ting has filed an amendment to his Schedule 13D, reporting a decrease in his beneficial ownership of Indaptus Therapeutics, Inc. The filing indicates that Ting has sold a total of 1,301,827 shares of the company's common stock, resulting in a new ownership stake of 9,948,173 shares, or approximately 6.48% of the company. This change is significant as it highlights adjustments in Ting's investment strategy in response to the company's recent capital activities.
Indaptus Therapeutics, Inc., classified under the SIC code for pharmaceutical preparations, is actively involved in the development and commercialization of innovative therapies. The company has been in the news for its recent private placement, which involved the issuance of 20,338,974 shares of common stock on October 16, 2026. This issuance has contributed to the dilution of existing shares, impacting shareholders like Ting.
According to the filing, Ting originally acquired 11,250,000 shares upon converting preferred stock in March 2026. Following his recent sales, he now holds 2,448,173 shares in a brokerage account and 7,500,000 shares in book-entry form. The filing states, "Ting Yang beneficially owns 9,948,173 shares of the Issuer's Common Stock," reflecting the changes in his holdings.
This decrease in ownership may affect both Ting's influence within the company and the market perception of Indaptus Therapeutics. As a significant shareholder, his decisions can impact stock performance and investor sentiment. The pharmaceutical preparations industry is known for its volatility, and changes in major shareholders often draw attention from analysts and investors alike.
Looking ahead, the filing does not specify what actions Ting may take next regarding his remaining shares or any further investments in Indaptus Therapeutics. However, the ongoing developments within the company and the broader market will likely influence his future decisions.